scholarly journals Effects of SuperUlam on Supporting Concentration and Mood: A Randomized, Double-Blind, Placebo-Controlled Crossover Study

2013 ◽  
Vol 2013 ◽  
pp. 1-10 ◽  
Author(s):  
Jay K Udani
Keyword(s):  
Working Memory ◽  
Reaction Time ◽  
Cognitive Function ◽  
Executive Functioning ◽  
Crossover Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Study Product ◽  
Total Mood Disturbance ◽  
Significant Difference

Background. SuperUlam is a proprietary blend of natural ingredients aimed at supporting brain health. We aimed to evaluate the effect of SuperUlam on attention and mood in healthy adults.Methods. Twenty healthy individuals aged 35–65 were enrolled in this randomized, double-blind, placebo-controlled, crossover study. Study duration was 3 weeks and consisted of 3 visits. Measurement of cognitive function included computer-based testing of reaction time, complex attention, working memory, sustained attention, and executive functioning. Mood testing was performed via the profile of mood states (POMS) survey and the Chalder fatigue scale.Results. Cognitive function testing demonstrated a significant improvement from baseline in executive functioning, cognitive flexibility, reaction time, and working memory in the product group only (P<0.05). When comparing the study product to placebo, the data demonstrated a significant decrease in tension, depression, and anger (P<0.05). There was no significant difference between the product and placebo in the other measures of mood, including vigor, fatigue, confusion, and total mood disturbance. No adverse events were reported.Conclusions.Supplementation with SuperUlam is safe to consume with potential benefits to cognitive function and mood.

Sulfisoxazole Chemoprophylaxis for Frequent Otitis Media

PEDIATRICS ◽  
1983 ◽  
Vol 71 (4) ◽  
pp. 524-530
Author(s):  
Thomas E. Liston ◽  
Col William S. Foshee ◽  
Maj Wayne D. Pierson
Keyword(s):  
Crossover Study ◽  
Otitis Media ◽  
Active Drug ◽  
Eustachian Tube Function ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Significant Difference ◽  
Tube Function ◽  
Carry Over ◽  
Carry Over Effect

Sulfisoxazole, 75 mg/kg/d in two divided doses for 3 months, was administered in a double-blind placebo crossover study to 35 children aged 6 months to 5 years who had frequent recurring episodes of otitis media. There was a 40% reduction in the rate of otitis media among patients receiving sulfisoxazole compared with those receiving placebo (0.25 v 0.42 episode per patient-month) which did not depend on age, sex, season, or several other factors. Using a randomized order, among patients who received placebo first, there was a 64% reduction on sulfisoxazole therapy compared with placebo (0.20 v 0.56 episode per patient-month). In this subgroup, there was significant improvement in eustachian tube function according to serial tympanograms. In the patients who received sulfisoxazole first, the rate of acute otitis remained low on placebo (0.28 v 0.30 episode per patient-month), and tympanogram patterns continued to improve after discontinuation of the active drug. These differences suggest a carry-over effect from the benefits of chemoprophylaxis. There was no significant difference in the species or sensitivity patterns of bacteria isolated from patients receiving sulfisoxazole or placebo. Sulfisoxazole chemoprophylaxis appears to be safe and effective in significantly reducing episodes of otitis media and improving tympanogram patterns.

scholarly journals Randomised, double-blind, placebo-controlled crossover study of single-dose guanfacine in unilateral neglect following stroke

2018 ◽  
Vol 89 (6) ◽  
pp. 593-598 ◽  
Author(s):  
Edwin S Dalmaijer ◽  
Korina M S Li ◽  
Nikos Gorgoraptis ◽  
Alexander P Leff ◽  
David L Cohen ◽  
...  
Keyword(s):  
Working Memory ◽  
Single Dose ◽  
Crossover Study ◽  
Functional Outcome ◽  
Sustained Attention ◽  
Spatial Working Memory ◽  
Double Blind ◽  
Unilateral Neglect ◽  
Directional Bias ◽  
Double Blind Placebo

ObjectiveUnilateral neglect is a poststroke disorder that impacts negatively on functional outcome and lacks established, effective treatment. This multicomponent syndrome is characterised by a directional bias of attention away from contralesional space, together with impairments in several cognitive domains, including sustained attention and spatial working memory. This study aimed to test the effects of guanfacine, a noradrenergic alpha-2A agonist, on ameliorating aspects of neglect.MethodsThirteen right hemisphere stroke patients with leftward neglect were included in a randomised, double-blind, placebo-controlled proof-of-concept crossover study that examined the effects of a single dose of guanfacine. Patients were tested on a computerised, time-limited cancellation paradigm, as well as tasks that independently assessed sustained attention and spatial working memory.ResultsOn guanfacine, there was a statistically significant improvement in the total number of targets found on the cancellation task when compared with placebo (mean improvement of 5, out of a possible 64). However, there was no evidence of a change in neglect patients’ directional attention bias. Furthermore, Bayesian statistical analysis revealed reliable evidence against any effects of guanfacine on search organisation and performance on our sustained attention and spatial working memory tasks.ConclusionsGuanfacine improves search in neglect by boosting the number of targets found but had no effects on directional bias or search organisation, nor did it improve sustained attention or working memory on independent tasks. Further work is necessary to determine whether longer term treatment with guanfacine may be effective for some neglect patients and whether it affects functional outcome measures.Trial registration numberNCT00955253.

scholarly journals Dose-Response of Paraxanthine on Cognitive Function: A Double Blind, Placebo Controlled, Crossover Trial

Nutrients ◽  
2021 ◽  
Vol 13 (12) ◽  
pp. 4478
Author(s):  
Dante Xing ◽  
Choongsung Yoo ◽  
Drew Gonzalez ◽  
Victoria Jenkins ◽  
Kay Nottingham ◽  
...  
Keyword(s):  
Reaction Time ◽  
Cognitive Function ◽  
Side Effects ◽  
Response Time ◽  
Blood Sample ◽  
Clinical Chemistry ◽  
Short Term ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Function Tests

Paraxanthine (PXN) is a metabolite of caffeine that has recently been reported to enhance cognition at a dose of 200 mg. Objective: To determine the acute and short-term (7-day) effects of varying doses of PXN on cognitive function and side effects. Methods: In a double blind, placebo-controlled, crossover, and counterbalanced manner, 12 healthy male and female volunteers (22.7 ± 4 years, 165 ± 7 cm, 66.5 ± 11 kg, 24.4 ± 3 kg/m2) ingested 200 mg of a placebo (PLA), 50 mg of PXN (ENFINITY™, Ingenious Ingredients, L.P.) + 150 mg PLA, 100 mg PXN + 100 mg PLA, or 200 mg of PXN. With each treatment experiment, participants completed side effect questionnaires and donated a fasting blood sample. Participants then performed a series of tests assessing cognition, executive function, memory, and reaction time. Participants then ingested one capsule of PLA or PXN treatments. Participants then completed side effects and cognitive function tests after 1, 2, 3, 4, 5, and 6 h of treatment ingestion. Participants continued ingesting one dose of the assigned treatment daily for 6-days and returned to the lab on day 7 to donate a fasting blood sample, assess side effects, and perform cognitive function tests. Participants repeated the experiment while ingesting remaining treatments in a counterbalanced manner after at least a 7-day washout period until all treatments were assessed. Results: The Sternberg Task Test (STT) 4-Letter Length Present Reaction Time tended to differ among groups (p = 0.06). Assessment of mean changes from baseline with 95% CI’s revealed several significant differences among treatments in Berg-Wisconsin Card Sorting Correct Responses, Preservative Errors (PEBL), and Preservative Errors (PAR Rules). There was also evidence of significant differences among treatments in the Go/No-Go Task tests in Mean Accuracy as well as several time points of increasing complexity among STT variables. Finally, there was evidence from Psychomotor Vigilance Task Test assessment that response time improved over the series of 20 trials assessed as well as during the 6-h experiment in the PXN treatment. Acute and short-term benefits compared to PLA were seen with each dose studied but more consistent effects appeared to be at 100 mg and 200 mg doses. No significant differences were observed among treatments in clinical chemistry panels or the frequency or severity of reported side effects. Results provide evidence that acute ingestion of 100 mg and 200 mg of PXN may affect some measures of cognition, memory, reasoning, and response time as well as help sustain attention. Additionally, that acute and daily ingestion of PXN for 7 days is not associated with any clinically significant side effects. Conclusions: PXN may serve as an effective nootropic agent at doses as low as 50 mg.

scholarly journals Further Evidence of Benefits to Mood and Working Memory from Lipidated Curcumin in Healthy Older People: A 12-Week, Double-Blind, Placebo-Controlled, Partial Replication Study

Nutrients ◽  
2020 ◽  
Vol 12 (6) ◽  
pp. 1678 ◽  
Author(s):  
Katherine H. M. Cox ◽  
David J. White ◽  
Andrew Pipingas ◽  
Kaylass Poorun ◽  
Andrew Scholey
Keyword(s):  
Working Memory ◽  
Stress Reactivity ◽  
Memory Performance ◽  
Replication Study ◽  
Partial Replication ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Total Mood Disturbance ◽  
And Performance ◽  
Present Trial

Curcumin (a flavonoid isolated from turmeric) affects several processes involved in neurocognitive aging. We have previously reported that short term (4-weeks) administration of a highly bioavailable curcumin preparation (Longvida©) improved working memory and reduced fatigue and stress reactivity in a healthy older cohort. The present trial (ACTRN12616000484448) was a partial replication study, evaluating similar effects at 4 and 12-weeks Longvida© supplementation. A double-blind, placebo-controlled, parallel-groups trial was conducted. Eighty participants aged 50–80 years (mean = 68.1, SD = 6.34) were randomised to receive Longvida© (400 mg daily containing 80 mg curcumin) or a matching placebo. Assessment took place at baseline then following 4 and 12 weeks treatment. Outcome measures included cognitive performance, mood and biomarkers. Compared with placebo, curcumin was associated with several significant effects. These included better working memory performance at 12-weeks (Serial Threes, Serial Sevens and performance on a virtual Morris Water Maze), and lower fatigue scores on the Profile of Mood States (POMS) at both 4 and 12-weeks, and of tension, anger, confusion and total mood disturbance at 4-weeks only. The curcumin group had significantly elevated blood glucose. These results confirm that Longvida© improves aspects of mood and working memory in a healthy older cohort. The pattern of results is consistent with improvements in hippocampal function and may hold promise for alleviating cognitive decline in some populations.

scholarly journals Lubiprostone improves visualization of small bowel for capsule endoscopy: a double-blind, placebo-controlled 2-way crossover study

2017 ◽  
Vol 05 (06) ◽  
pp. E424-E429
Author(s):  
Mizue Matsuura ◽  
Masahiko Inamori ◽  
Yumi Inou ◽  
Kenji Kanoshima ◽  
Takuma Higurashi ◽  
...  
Keyword(s):  
Small Bowel ◽  
Image Quality ◽  
Crossover Study ◽  
Transit Time ◽  
Capsule Endoscopy ◽  
Secondary Outcome ◽  
Serious Adverse Events ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Significant Difference

Abstract Background and study aims Lubiprostone has been reported to be an anti-constipation drug. The aim of the study was to investigate the usefulness of lubiprostone both for bowel preparation and as a propulsive agent in small bowel endoscopy. Patients and methods This was a double-blind, placebo-controlled, 2-way crossover study of subjects who volunteered to undergo capsule endoscopy (CE). A total of 20 subjects (16 male and 4 female volunteers) were randomly assigned to receive a 24-μg tablet of lubiprostone 120 minutes prior to capsule ingestion for CE (L regimen), or a placebo tablet 120 minutes prior to capsule ingestion for CE (P regimen). Main outcome was gastric transit time (GTT) and small-bowel transit time (SBTT). Secondary outcome was adequacy of small-bowel cleansing and the fluid score in the small bowel. The quality of the capsule endoscopic images and fluid in the small bowel were assessed on 5-point scale. Results The capsule passed into the small bowel in all cases. Median GTT was 57.3 (3 – 221) minutes for the P regimen and 61.3 (10 – 218) minutes for the L regimen (P = 0.836). Median SBTT was 245.0 (164 – 353) minutes for the P regimen and 228.05 (116 – 502) minutes for the L regimen (P = 0.501). The image quality score in the small bowel was 3.05 ± 1.08 for the P regimen and 3.80 ± 0.49 for the L regimen (P < 0.001). The fluid score in the small bowel was 2.04 ± 1.58 for the P regimen and 2.72 ± 1.43 for the L regimen (P < 0.001). There was a significant difference between the 2 regimens with regard to image quality. The fluid score was more plentiful for the L regimen than for the P regimen. There were no cases of capsule retention or serious adverse events in this study. Conclusion Our study showed that use of lubiprostone prior to CE significantly improved visualization of the small bowel during CE as a result of inducing fluid secretion into the small bowel.

The effect of glucose dose and fasting interval on cognitive function: a double-blind, placebo-controlled, six-way crossover study

2011 ◽  
Vol 220 (3) ◽  
pp. 577-589 ◽  
Author(s):  
Lauren Owen ◽  
Andrew B. Scholey ◽  
Yvonne Finnegan ◽  
Henglong Hu ◽  
Sandra I. Sünram-Lea
Keyword(s):  
Cognitive Function ◽  
Crossover Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Effect Of Glucose

Effect of Stevia on Glycemic and Insulin Responses in Obese Patients—A Randomized, Double-Blind, Placebo-Controlled Crossover Study

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 790-P
Author(s):  
PARINYA SAMAKKARNTHAI ◽  
MANAPORN PAYANUNDANA ◽  
NATTAPOL SATHAVARODOM ◽  
CHONPITI SIRIWAN ◽  
APUSSANEE BOONYAVARAKUL
Keyword(s):  
Crossover Study ◽  
Obese Patients ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Insulin Responses
Sign in / Sign up

Export Citation Format

Share Document